Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025HaematologicaOpen Access

Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJonathan BordatÉKÉléonore KaphanMRMarie Robin

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved overall survival and reduced non-relapse mortality with PTCY versus antithymocyte globulin in HLA-mismatched transplants.

Key Points

  • Improved overall survival with post-transplant cyclophosphamide, achieving 78.7% compared to 56.5% with high-dose ATG.
  • One-year non-relapse mortality was significantly lower at 7.7% in the PTCY group versus 24.4% in high-dose ATG.
  • Analysis involved 155 HLA-mismatched unrelated donor stem cell transplantation recipients, highlighting the effectiveness of PTCY.
  • Post-transplant cyclophosphamide may help reduce graft-versus-host disease mortality while providing similar infection rates.

Cite This Study

Bordat et al. (2025) studied this question.

synapsesocial.com/papers/68bb3efd2b87ece8dc957e33https://doi.org/10.3324/haematol.2024.287157
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Unrelated donor transplantation with post-transplant cyclophosphamide versus ATG for myelodysplastic neoplasms2024 · 5 citations
  2. 2PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation2024 · 44 citations
  3. 3Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation2019 · 180 citations
  4. 4Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation.2025 · 5 citations
  5. 5ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?2024 · 36 citations